4-Hydroxytamoxifen (Afimoxifene) vs Clascoterone (CB-03-01)

Hormone

Cosmetic

Research Only

Research Only

Afimoxifene is a competitive antagonist/partial agonist at estrogen receptors alpha and beta, exhibiting tissue-selective activity characteristic of SERMs. Receptor-binding studies on estrogen receptors isolated from human breast carcinoma found 4-hydroxytamoxifen binds ER with affinity equal to estradiol and 25–50× higher than tamoxifen itself, which is why it is considered tamoxifen's principal active metabolite despite low circulating abundance (2–18% of parent drug). Unlike tamoxifen and endoxifen, whose formation depends on hepatic CYP2D6/CYP3A4 activity, 4-hydroxytamoxifen is already the pharmacologically active hydroxylated species, which is the rationale for delivering it directly (e.g., as a topical gel) to bypass variable CYP2D6-dependent bioactivation of oral tamoxifen.

Clascoterone is a competitive androgen receptor (AR) antagonist that binds the AR in skin (sebocytes, hair-follicle tissue) and competes with dihydrotestosterone (DHT) for receptor binding, blocking DHT-driven transcription of androgen-responsive genes tied to sebum production and inflammation (in vitro human sebocyte data, Rosette et al. 2019, PMID 31141847). The FDA-approved Winlevi prescribing information states plainly, 'The mechanism of action of WINLEVI cream for the topical treatment of acne vulgaris is unknown' (FDA label, Section 12.1)—so while AR-antagonist binding is established, the clinical mechanism producing the acne benefit is formally unconfirmed per the regulator-reviewed label. Clascoterone does not inhibit skin 5α-reductase (Celasco et al. 2004, PMID 15646372).